Proteinuria After Kidney Transplantation
Pediatric Transplantation · 2025-12 · 29 (8)
DOI: 10.1111/petr.70233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Transplantation, online erschienen am 24.11.2025. Verfasst von Tomas Seeman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Second Faculty of Medicine, Charles University, Prague, Czechia. Hauptthemen laut MEDLINE: Kidney Transplantation, Proteinuria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conceptual Development of Research Organization.
Abstract (Originalsprache)
Proteinuria is a relatively frequent complication in both adults and children after kidney transplantation (40%–80%). It is usually mild and predominantly of tubular origin and is caused mainly by rejection, mTOR inhibitors, or hypertension; however, proteinuria could also be in the nephrotic range and of glomerular origin if caused by the recurrence of idiopathic FSGS or rejection. Proteinuria is a risk factor impacting graft and patient survival in adults and graft survival in children. Proteinuria should be assessed by protein/creatinine ratio regularly in pediatric kidney transplant recipients. In children with idiopathic FSGS, proteinuria should be assessed daily during the first 2–3 weeks post‐transplant to enable prompt diagnosis of recurrence. The etiology of proteinuria should be identified (recurrence, rejection, mTOR‐inhibitors, hypertension, etc.). If no apparent cause is found, a graft biopsy should be considered. Antiproteinuric therapy is primarily focused on treating the causes of the proteinuria, and this is usually done using Angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs). The long‐term follow‐up goal should be normalization of proteinuria with a protein/creatinine ratio < 20 mg/mmol (200 mg/g). Because of the role elevated blood pressure may play in exacerbating proteinuria, antihypertensive medications should be used in those who are resistant to initial antiproteinuric therapy to achieve lower BP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Second Faculty of Medicine, Charles University, Prague, Czechia.
- Department of Pediatrics, University Hospital Ostrava and Medical Faculty University of Ostrava, Ostrava, Czechia.
- Children's Hospital of Eastern Ontario Research Institute & Children's Hospital of Eastern Ontario, Division of Pediatric Nephrology, University of Ottawa, Ottawa, Ontario, Canada.
- Kidney Research Center, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
- Division of Pediatric Nephrology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland.
- Division of Pediatric Nephrology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Tomas Seeman, Robert L Myette, Janusz Feber, Massimiliano Bertacchi, Raja Sekhar Dandamudi
Förderung
- Conceptual Development of Research Organization
Zitieren
APA
Seeman, T., Myette, R. L., Feber, J., Bertacchi, M., Dandamudi, R. S., Erez, D. L., & Buescher, A. (2025). Proteinuria After Kidney Transplantation. Pediatric Transplantation, 29(8). https://doi.org/10.1111/petr.70233
Vancouver
Seeman T, Myette RL, Feber J, Bertacchi M, Dandamudi RS, Erez DL, et al. Proteinuria After Kidney Transplantation. Pediatric Transplantation. 2025;29(8). doi:10.1111/petr.70233
BibTeX
@article{Seeman2025,
author = {Seeman, Tomas and Myette, Robert L and Feber, Janusz and Bertacchi, Massimiliano and Dandamudi, Raja Sekhar and Erez, Daniella Levy and Buescher, Anja},
title = {Proteinuria After Kidney Transplantation},
journal = {Pediatric Transplantation},
year = {2025},
volume = {29},
number = {8},
doi = {10.1111/petr.70233}
}
EUVIMED